Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2026-03-08 @ 11:22 PM
Study NCT ID:
NCT03923634
Status:
COMPLETED
Last Update Posted:
2024-12-10
First Post:
2019-04-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Princess® RICH for the Correction of Fine Lines
Sponsor:
Croma-Pharma GmbH
Organization:
Study Overview
Official Title:
A Prospective Open-label, Multicenter Study Evaluating Princess® RICH in Correction of Fine Lines
Status:
COMPLETED
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RICH
Brief Summary:
Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: